ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
+25.85%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$148M
AUM Growth
+$148M
(+15%)
Cap. Flow
+$5.66M
Cap. Flow
% of AUM
3.84%
Top 10 Holdings %
Top 10 Hldgs %
61.6%
Holding
48
New
13
Increased
13
Reduced
7
Closed
11
Top Buys
| 1 |
Disc Medicine
IRON
|
$6.19M |
| 2 |
Praxis Precision Medicines
PRAX
|
$4.89M |
| 3 |
Clene
CLNN
|
$3.73M |
| 4 |
IMA
ImageneBio, Inc. Common Stock
IMA
|
$3.66M |
| 5 |
Immunovant
IMVT
|
$2.69M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$5.86M |
| 2 |
United Therapeutics
UTHR
|
$5.26M |
| 3 |
CBAY
Cymabay Therapeutics
CBAY
|
$4.91M |
| 4 |
BLU
BELLUS Health Inc.
BLU
|
$4.55M |
| 5 |
Sarepta Therapeutics
SRPT
|
$4.52M |
Sector Composition
| 1 | Healthcare | 97.46% |
| 2 | Consumer Staples | 2.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $27.1M | 18.37% | 297,596 +7,096 | +2% | +$646K |
|
|
WHWK
2
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $12.6M | 8.57% | 1,849,402 | – | – |
|
3
Terns Pharmaceuticals
TERN
$609M
| $8.49M | 5.75% | 970,000 -129,309 | -12% | -$1.13M |
|
4
Kura Oncology
KURA
$686M
| $7.5M | 5.08% | 709,118 +143,861 | +25% | +$1.52M |
|
5
Syndax Pharmaceuticals
SNDX
$1.41B
| $6.28M | 4.25% | 299,841 -30,159 | -9% | -$631K |
|
|
6
Disc Medicine
IRON
$2.07B
| $6.19M | 4.2% | +139,500 | New | +$6.19M |
|
7
Vaxcyte
PCVX
$4B
| $6.1M | 4.13% | 122,166 +1,666 | +1% | +$83.2K |
|
8
Rocket Pharmaceuticals
RCKT
$354M
| $6.08M | 4.12% | 306,194 +8,194 | +3% | +$163K |
|
9
Viridian Therapeutics
VRDN
$1.5B
| $5.35M | 3.62% | 224,707 +56,707 | +34% | +$1.35M |
|
|
ISEE
10
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $5.17M | 3.5% | 131,454 -149,046 | -53% | -$5.86M |
|
11
argenx
ARGX
$43.6B
| $4.9M | 3.32% | 12,568 +2,974 | +31% | +$1.16M |
|
|
12
Praxis Precision Medicines
PRAX
$958M
| $4.89M | 3.31% | +4,250,000 | New | +$4.89M |
|
13
Ventyx Biosciences
VTYX
$171M
| $4.83M | 3.27% | 147,318 -61,182 | -29% | -$2.01M |
|
|
CBAY
14
DELISTED
Cymabay Therapeutics
CBAY
| $4.71M | 3.19% | 430,000 -448,500 | -51% | -$4.91M |
|
15
Celldex Therapeutics
CLDX
$1.47B
| $4.15M | 2.81% | 122,343 +843 | +0.7% | +$28.6K |
|
|
16
Clene
CLNN
$53.1M
| $3.73M | 2.53% | +4,240,846 | New | +$3.73M |
|
|
IMA
17
ImageneBio, Inc. Common Stock
IMA
$150M
| $3.66M | 2.48% | +558,000 | New | +$3.66M |
|
18
EyePoint Pharmaceuticals
EYPT
$797M
| $3.32M | 2.25% | 382,000 +78,604 | +26% | +$684K |
|
19
GH Research
GHRS
$837M
| $2.9M | 1.97% | 244,828 +1,578 | +0.6% | +$18.7K |
|
|
20
Immunovant
IMVT
$2.56B
| $2.69M | 1.82% | +141,755 | New | +$2.69M |
|
21
Verastem
VSTM
$569M
| $2.23M | 1.51% | +300,000 | New | +$2.23M |
|
22
Roivant Sciences
ROIV
$8.15B
| $2.22M | 1.5% | +220,000 | New | +$2.22M |
|
23
Enliven Therapeutics
ELVN
$1.2B
| $2.13M | 1.45% | 104,500 +73,521 | +237% | +$1.5M |
|
24
Alkermes
ALKS
$4.78B
| $1.4M | 0.95% | 44,689 +13,000 | +41% | +$407K |
|
25
Aclaris Therapeutics
ACRS
$209M
| $1.26M | 0.86% | 121,692 -148 | -0.1% | -$1.54K |
|